Why a Stopped MS Drug‑Withdrawal Trial Sparked Pushback

# Overview A randomized trial examined whether adults with multiple sclerosis who had at least five years of clinical and radiographic stability could safely stop their disease‑modifying therapy (DMT). The trial randomized patients to either discontinuation or continuation of their DMT. The discontinuation group experienced relapses at a substantially higher rate, mostly detected radiographically. The trial was stopped early after 15 months because of the difference.

# Why the trial matters The question is practical and common: can people with long‑standing stable MS stop maintenance DMT? This trial provides prospective randomized data in a middle‑aged population with prolonged stability, a population not well represented in prior studies that focused on older patients. The findings challenge a straightforward strategy of stopping therapy after long clinical quietness.

# What the data showed

• Patients were adults (>18 years) with ≥5 years of clinical and radiographic stability.

• The continuation arm had zero relapses in the reported follow‑up.
• The trial was terminated early after 15 months because of the imbalance in relapse rates.

# Limits on how to use these results This trial was performed in Europe and examined mainly first‑line DMTs, specifically β interferons and glatiramer acetate. It did not evaluate newer, higher‑efficacy agents such as B‑cell‑depleting therapies or natalizumab. Therefore, you cannot generalize these outcomes to patients who are stable while on modern high‑efficacy treatment. The trial's early stoppage and the middle‑aged composition of the cohort also affect how broadly to apply the findings.

# The blog response and its critique The MS‑focused blog post questions labeling this study "Trial of the Year," arguing that calling a negative or stopped trial the top trial is odd. The author points out that, since the trial largely addressed older first‑line drugs, it may be better described as a study relevant to earlier generations of MS therapy rather than to current practice where potent agents are used earlier in some regions.

# Related preclinical work mentioned The blog also summarizes a separate mouse study that used CD7‑targeted lipid nanoparticles carrying circular RNA to program T cells in situ to express EBNA1‑specific CARs. In that MS mouse model, these in situ CAR‑T cells eliminated EBNA1‑specific B cells and reduced disease measures. The blog notes that this is preclinical work and includes a comment that the outcome might more accurately be framed as reduced inflammation rather than curing MS.

# Practical takeaways for clinicians and patients

• Apply these findings cautiously to patients on modern high‑efficacy therapies because the trial focused on older agents.
• Decisions about stopping therapy should remain individualized and include discussion of the evidence gaps for different DMT classes, patient preferences, and monitoring plans.

# Bottom line The randomized trial provides prospective evidence that discontinuing first‑line DMTs after prolonged stability carries relapse risk substantial enough that the study was stopped early. The result is important for conversations about stopping therapy but does not resolve whether the same risk applies to patients on contemporary high‑efficacy treatments. The accompanying preclinical CAR‑T approach is an early experimental avenue and not ready to inform clinical practice.